华东医药上半年净利18.15亿元 同比增长7.01%

Core Insights - The company reported a revenue of 21.675 billion with a year-on-year growth of 3.39% and a net profit attributable to shareholders of 1.815 billion, reflecting a year-on-year increase of 7.01% [2] Financial Performance - The company's revenue for the first half of the year reached 21.675 billion, marking a 3.39% increase compared to the same period last year [2] - The net profit attributable to shareholders was 1.815 billion, which represents a 7.01% growth year-on-year [2] Product Development - The sales of newly approved innovative drugs have become a core driver for the continuous growth of the pharmaceutical industry [2] - The CAR-T product, Zewokaiolun Injection (brand name: Saikeze), has completed certification and registration, with coverage in over 20 provinces and cities nationwide by mid-2025 [2] - The company has issued 111 valid orders to its partner, Kexi Pharmaceutical [2]